New Drug Plozasiran Nears FDA Approval for Familial Chylomicronemia Syndrome

The U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) for plozasiran, a potential first-in-class treatment for Familial Chylomicronemia Syndrome (FCS), a rare and life-threatening genetic disorder. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025, for its decision.

What is Plozasiran and How Does It Work?

Plozasiran, developed by Arrowhead, is an investigational RNA interference (RNAi) drug. It works by targeting apolipoprotein C-III (APOC3), a key protein that regulates triglyceride metabolism. By reducing APOC3, plozasiran helps the body remove triglyceride-rich lipoproteins, directly addressing the underlying metabolic issue in FCS. This mechanism is distinct from traditional lipid-lowering drugs, which have had limited success in treating this condition.

Key Findings from the Phase 3 PALISADE Trial

The NDA is supported by data from the Phase 3 PALISADE trial, which enrolled 75 adults with FCS. The trial’s results were highly encouraging:

Triglyceride Reduction: At month 10, the median triglyceride levels were significantly reduced by 80% in patients receiving the 25 mg dose and 78% with the 50 mg dose, compared to only a 17% reduction in the placebo group.
Pancreatitis Risk Reduction: Most importantly, plozasiran reduced the risk of acute pancreatitis—a life-threatening complication of FCS—by 83%. Only two patients on plozasiran experienced a pain episode during the study, compared to seven in the placebo group.
Safety Profile: The drug was well-tolerated, with adverse events being similar across all groups. Serious adverse events were more common in the placebo group.

The Pharmacist’s Role and Future Potential

If approved, plozasiran will represent a major breakthrough, offering a new treatment option for a disease with a significant unmet medical need. Pharmacists will play a critical role in its integration into clinical practice. They will be responsible for counseling patients on the drug’s mechanism of action, its quarterly dosing schedule, and the continued importance of a strict diet.

The potential of plozasiran may also extend beyond FCS. Arrowhead is conducting additional Phase 3 trials to evaluate the drug’s efficacy in patients with other conditions, such as severe hypertriglyceridemia and mixed hyperlipidemia. The results of these trials are expected to be released in 2026, which could broaden the drug’s use for a wider population at risk of cardiovascular and metabolic complications.